Marisa holds an MS in Cellular and Molecular Pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. She specializes in cancer biology, immunology, and genetics. Marisa began working with BioNews in 2018, and has written about science and health for SelfHacked and the Genetics Society of America. She also writes/composes musicals and coaches the University of Pittsburgh fencing club.
After unanimous votes by the boards of directors of both companies, AstraZeneca has announced it will acquire Alexion Pharmaceuticals. If the acquisition gets all needed regulatory clearances, as well ... Read more
The National Organization for Rare Disorders (NORD)’s RareLaunch training program will host two days of free virtual workshops in December, with the aim of empowering leaders to start non-profit ... Read more
A majority of rare disease patients using telehealth during the COVID-19 pandemic thought the experience positive, and many would like the option of continuing its use in future appointments, a ... Read more
Treatment with Argenx‘s investigational therapy efgartigimod leads to significant and early reductions in the severity of generalized myasthenia gravis (gMG), regardless of the presence of antibodies against acetylcholine receptor ... Read more
Altered levels of immune proteins associated with the complement system may be implicated in generalized myasthenia gravis (MG), a new study suggests. The study, “Changes in serum complements and ... Read more
A patient with three different types of myasthenia gravis (MG)-associated antibodies was described in a recent case report. The report, “Anti-MuSK positive myasthenia gravis with anti-Lrp4 and anti-titin antibodies,” ... Read more
Treatment with IMVT-1401 significantly eased symptoms and lowered antibody levels in adults with moderate-to-severe generalized myasthenia gravis (MG), top-line results of a small Phase 2a trial show. Use of ... Read more